TipRanks
Advertisement
Advertisement

BOLT Stock Latest News

Bolt Biotherapeutics Amends Lease, Reduces Facility Obligations
Company AnnouncementsBolt Biotherapeutics Amends Lease, Reduces Facility Obligations
3d ago
8K
BOLT
Bolt Biotherapeutics reports Q2 EPS ($4.57) vs. ($4.46) last year
PremiumThe Fly
Bolt Biotherapeutics reports Q2 EPS ($4.57) vs. ($4.46) last year
2M ago
BOLT
BOLT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
BOLT Upcoming Earnings Report: What to Expect?
2M ago
BOLT
Bolt Biotherapeutics Holds 2026 Annual Stockholder Meeting
PremiumCompany Announcements
Bolt Biotherapeutics Holds 2026 Annual Stockholder Meeting
4M ago
8K
BOLT
Bolt Biotherapeutics initiated with a Buy at Rodman & Renshaw
PremiumThe Fly
Bolt Biotherapeutics initiated with a Buy at Rodman & Renshaw
4M ago
BOLT
Buy Rating on Bolt Biotherapeutics Driven by Differentiated Claudin 18.2 ISAC BDC-4182 and Solid Cash Runway to 2027
PremiumRatingsBuy Rating on Bolt Biotherapeutics Driven by Differentiated Claudin 18.2 ISAC BDC-4182 and Solid Cash Runway to 2027
7M ago
BOLT
Bolt Biotherapeutics reports Q4 EPS ($3.84), consensus ($5.52)
Premium
The Fly
Bolt Biotherapeutics reports Q4 EPS ($3.84), consensus ($5.52)
7M ago
BOLT
Buy Rating for Bolt Biotherapeutics: Innovative Approach and Strong Financials Drive Positive Outlook
Premium
Ratings
Buy Rating for Bolt Biotherapeutics: Innovative Approach and Strong Financials Drive Positive Outlook
11M ago
BOLT
Bolt Biotherapeutics Reports Improved Financial Performance
PremiumCompany Announcements
Bolt Biotherapeutics Reports Improved Financial Performance
11M ago
BOLT
Bolt Biotherapeutics reports Q3 EPS ($3.72), consensus ($5.39)
PremiumThe Fly
Bolt Biotherapeutics reports Q3 EPS ($3.72), consensus ($5.39)
11M ago
BOLT
Bolt Biotherapeutics’ Pioneering Study on BDC-4182: A New Hope for Cancer Treatment
PremiumCompany Announcements
Bolt Biotherapeutics’ Pioneering Study on BDC-4182: A New Hope for Cancer Treatment
12M ago
BOLT
Buy Rating for Bolt Biotherapeutics: Innovative Cancer Treatment Approach and Strategic Financial Management
PremiumRatings
Buy Rating for Bolt Biotherapeutics: Innovative Cancer Treatment Approach and Strategic Financial Management
12M ago
BOLT
Bolt Biotherapeutics assumed with a Buy at H.C. Wainwright
PremiumThe FlyBolt Biotherapeutics assumed with a Buy at H.C. Wainwright
12M ago
BOLT
Bolt Biotherapeutics Announces Major Restructuring Plan
Premium
Company Announcements
Bolt Biotherapeutics Announces Major Restructuring Plan
1y ago
8K
BOLT
Bolt Biotherapeutics to reduce workforce by 50%, gives update on BDC-4182 study
Premium
The Fly
Bolt Biotherapeutics to reduce workforce by 50%, gives update on BDC-4182 study
1y ago
BOLT
Bolt Biotherapeutics Reports Reduced Losses and Revenue Growth
PremiumCompany Announcements
Bolt Biotherapeutics Reports Reduced Losses and Revenue Growth
1y ago
BOLT
Cautious Hold Rating on Bolt Biotherapeutics Amid Uncertain Trial Outcomes and Financial Sustainability
PremiumRatings
Cautious Hold Rating on Bolt Biotherapeutics Amid Uncertain Trial Outcomes and Financial Sustainability
1y ago
BOLT
Bolt Biotherapeutics target adjusted to $75 at Lake Street after reverse split
PremiumThe Fly
Bolt Biotherapeutics target adjusted to $75 at Lake Street after reverse split
1y ago
BOLT
Bolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)
PremiumThe Fly
Bolt Biotherapeutics reports Q2 EPS ($4.46), consensus ($6.27)
1y ago
BOLT
Bolt Biotherapeutics Inc trading halted, news pending
PremiumThe FlyBolt Biotherapeutics Inc trading halted, news pending
1y ago
BOLT
Bolt Biotherapeutics Announces Reverse Stock Split
Premium
Company Announcements
Bolt Biotherapeutics Announces Reverse Stock Split
1y ago
8K
BOLT
Bolt Biotherapeutics Announces Reverse Stock Split Approval
Premium
Company Announcements
Bolt Biotherapeutics Announces Reverse Stock Split Approval
1y ago
8K
BOLT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >